[177Lu]Lu-PSMA治疗作为高级别胶质瘤患者的个体化治疗方式:剂量学结果与关键性陈述
本研究探讨[177Lu]Lu-PSMA作为个体化治疗手段用于高级别胶质瘤患者,重点进行治疗后剂量学分析。3例患者接受中位6.03 GBq(IQR 5.74-6.10)的[177Lu]Lu-PSMA治疗,采用平面全身显像与SPECT/CT混合方案进行剂量学评估。结果示肿瘤中位剂量0.56 Gy(IQR 0.36-1.25 Gy),低于外照射放疗所用剂量,作者对治疗有效性提出质疑。
要点
- 3例高级别胶质瘤患者接受中位6.03 GBq [177Lu]Lu-PSMA治疗。
- 肿瘤中位吸收剂量0.56 Gy(IQR 0.36-1.25 Gy),低于外照射放疗剂量。
- 作者认为该治疗有效性存疑。
核心结论
- 由于治疗后肿瘤吸收剂量低于外照射放疗所用剂量,该治疗的有效性存疑。
研究设计与样本
- 3例高级别胶质瘤患者接受[177Lu]Lu-PSMA个体化治疗,中位给药活度6.03 GBq(IQR 5.74-6.10 GBq)。
- 治疗后剂量学采用平面全身显像(注射后2、24、48小时)与SPECT/CT(注射后48小时)的混合方案进行。
- 1例患者在注射后8天追加平面全身显像。
主要发现
- 肿瘤中位吸收剂量为0.56 Gy(IQR 0.36-1.25 Gy)。
- 风险器官中位吸收剂量为0.27 Gy(IQR 0.16-0.57 Gy)。
- 肾脏中位吸收剂量为2.13 Gy(IQR 1.55-2.89 Gy)。
- 唾液腺中位吸收剂量为0.76 Gy(IQR 0.70-1.20 Gy)。
- 全身暴露为0.11 Gy(IQR 0.06-0.18 Gy)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 作者指出治疗后肿瘤吸收剂量低于外照射放疗所用剂量,据此对治疗有效性提出质疑。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The theranostic use of prostate-specific membrane antigen (PSMA) appears to be promising in patients with high-grade glioma. This study investigated [177Lu]Lu-PSMA therapy as an individual treatment approach with a focus on intratherapeutic dosimetry. Methods: Three patients were treated with a median of 6.03 GBq (interquartile range [IQR], 5.74-6.10) of [177Lu]Lu-PSMA. Intratherapeutic dosimetry was performed using a hybrid scenario with planar whole-body scintigraphy at 2, 24, and 48 h after treatment injection and SPECT/CT at 48 h after injection. Additive whole-body scintigraphy at 8 d after injection was performed on 1 patient. Results: The median doses were 0.56 Gy (IQR, 0.36-1.25 Gy) to tumor, 0.27 Gy (IQR, 0.16-0.57 Gy) to risk organs, 2.13 Gy (IQR, 1.55-2.89 Gy) to kidneys, and 0.76 Gy (IQR, 0.70-1.20 Gy) to salivary glands. Whole-body exposure was 0.11 Gy (IQR, 0.06-0.18 Gy). Conclusion: Because the intratherapeutic tumor dose is lower than that used in external radiation oncology, the effectiveness of treatment is questionable.
引用
- Graef J, Bluemel S, Brenner W, et al. [177Lu]Lu-PSMA Therapy as an Individual Treatment Approach for Patients with High-Grade Glioma: Dosimetry Results and Critical Statement. J Nucl Med. 2023. PMID: 37116918. doi:10.2967/jnumed.122.264850
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。